KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short term Debt (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Short term Debt data on record, last reported at $630.9 million in Q3 2025.

  • For Q3 2025, Short term Debt rose 1318.83% year-over-year to $630.9 million; the TTM value through Sep 2025 reached $630.9 million, up 1318.83%, while the annual FY2023 figure was $44.3 million, N/A changed from the prior year.
  • Short term Debt reached $630.9 million in Q3 2025 per IONS's latest filing, roughly flat from $630.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $630.9 million in Q3 2025 and bottomed at $3.5 million in Q4 2021.
  • Average Short term Debt over 5 years is $122.1 million, with a median of $44.4 million recorded in 2024.
  • Peak YoY movement for Short term Debt: tumbled 98.86% in 2021, then surged 1318.83% in 2025.
  • A 5-year view of Short term Debt shows it stood at $3.5 million in 2021, then skyrocketed by 40.95% to $5.0 million in 2022, then soared by 791.99% to $44.3 million in 2023, then grew by 0.3% to $44.5 million in 2024, then soared by 1318.83% to $630.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $630.9 million in Q3 2025, $630.1 million in Q2 2025, and $44.5 million in Q3 2024.